Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multidimensional burden of scarring alopecia in women: findings from the CAPAIR study.

International journal of women's dermatology·2026
Same author

Atopic Dermatitis: New Targets and Emerging Systemic Therapies.

American journal of clinical dermatology·2026
Same author

The biological role of CCR4 and its ligands CCL17 and CCL22 in atopic dermatitis: therapeutic implications and future directions.

Expert opinion on therapeutic targets·2026
Same author

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).

Dermatology and therapy·2026
Same author

Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.

The Journal of dermatological treatment·2026
Same author

Serum proteomic and single-cell transcriptomic profiling reveals immunoproteomic features distinguishing early-stage mycosis fungoides from atopic dermatitis.

The Journal of investigative dermatology·2026

Related Experiment Video

Updated: Jan 28, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.1K

What's New in Atopic Dermatitis.

Yael Renert-Yuval1, Emma Guttman-Yassky2

  • 1Department of Dermatology, Hadassah-Hebrew University Medical Center, Hadassah Ein-Kerem Medical Center, POB13000, Jerusalem, Israel.

Dermatologic Clinics
|March 10, 2019
PubMed
Summary

Discoveries in atopic dermatitis (AD) pathogenesis are improving patient management. While dupilumab offers targeted treatment, new options are needed due to varied patient responses and disease heterogeneity.

Keywords:
Atopic dermatitisCrisaboroleDupiluambFezakinumabGBR 830JAK inhibitorsLebrikizumabTralokinumab

More Related Videos

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

1.2K
Infecting Mice with Malassezia spp. to Study the Fungus-Host Interaction
06:19

Infecting Mice with Malassezia spp. to Study the Fungus-Host Interaction

Published on: November 6, 2019

13.6K

Related Experiment Videos

Last Updated: Jan 28, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.1K
Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

1.2K
Infecting Mice with Malassezia spp. to Study the Fungus-Host Interaction
06:19

Infecting Mice with Malassezia spp. to Study the Fungus-Host Interaction

Published on: November 6, 2019

13.6K

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Atopic dermatitis (AD) is a common inflammatory skin condition with complex pathogenesis.
  • Current treatments, including dupilumab, offer targeted therapies but do not benefit all patients.
  • The heterogeneous nature of AD necessitates the development of diverse therapeutic strategies.

Purpose of the Study:

  • To review recent advancements in understanding atopic dermatitis pathogenesis.
  • To highlight emerging and pipeline treatments for atopic dermatitis.
  • To discuss the potential impact of new therapies on the treatment paradigm for AD.

Main Methods:

  • Literature review of recent scientific discoveries in atopic dermatitis.
  • Analysis of ongoing and pipeline clinical trials for AD treatments.
  • Synthesis of current knowledge on AD pathogenesis and therapeutic targets.

Main Results:

  • Dupilumab, a targeted therapy, was the first approved agent for AD, demonstrating the efficacy of cytokine antagonism.
  • Not all patients respond to dupilumab, underscoring the need for alternative treatments.
  • Ongoing research is exploring novel therapeutic targets and agents for AD.

Conclusions:

  • Continued research into AD pathogenesis is crucial for developing more effective treatments.
  • Emerging therapies hold promise for expanding treatment options and improving outcomes for AD patients.
  • The evolving landscape of AD treatment is expected to redefine the management of this prevalent skin disease.